What Is a Depot Injection and How Does It Work?

A depot injection is a shot, usually given into muscle or under the skin, that creates a reservoir of medication designed to release slowly over weeks or months. Instead of taking a pill every day, you get a single injection and the drug trickles into your bloodstream at a controlled rate until the reservoir runs out. Depot formulations now cover a wide range of conditions, from schizophrenia and contraception to HIV prevention and opioid addiction, and the technology behind them has grown considerably more sophisticated since the first versions appeared in the 1960s.

How the Drug Releases Slowly

The word “depot” comes from the French for “storehouse,” and that is exactly what happens at the injection site. The formulation creates a physical store of medication in your tissue, and the drug gradually moves from that store into the surrounding fluid and then into your blood. How that release is engineered depends on the formulation type.

One common approach uses tiny polymer microspheres made from materials like polylactide-co-glycolide (PLGA) or polylactic acid (PLA). The drug is encapsulated inside these microspheres, which slowly break down in the body over days or months, releasing their contents as they degrade. These biodegradable polymers have been used in approved products for decades and can maintain a relatively constant drug level in the blood for extended periods.¹ The release from these systems tends to follow a three-phase pattern: a quick initial burst as drug near the surface escapes, a steady middle phase where the polymer slowly erodes and lets drug diffuse out, and then a final phase of faster release as the remaining polymer breaks down more rapidly.²

Another approach involves oil-based solutions. The drug is dissolved in an oily vehicle and injected into muscle or subcutaneous fat, where it slowly partitions out of the oil and into the watery tissue fluid surrounding it. How lipophilic (fat-loving) the drug is plays a major role in how long it takes to escape the oil depot.³ A third category uses formulations that are liquid when injected but turn into a gel once they meet body temperature, a change in pH, or contact with tissue fluids. The gel then acts as the slow-release reservoir.⁴

Where and How They Are Administered

Most depot injections go into one of two places: intramuscularly (into a large muscle, often the gluteal or deltoid) or subcutaneously (into the fat layer just under the skin, often in the abdomen, thigh, or upper arm). The choice matters. Muscle tissue has a richer blood supply, which can speed the initial absorption of some formulations. Subcutaneous tissue absorbs more slowly, which can actually be an advantage when you want a very gradual release.

For intramuscular depot injections, clinicians sometimes use a technique called the Z-track method, where the skin is pulled to one side before the needle goes in and then released afterward. This displaces the tissue layers so the needle track does not form a straight channel back to the surface, which helps prevent the medication from leaking out. Randomized trials have found that this approach reduces drug leakage at the injection site and lowers inflammation compared to standard injection technique.⁵ Some research also shows reduced leakage with the Z-track method, though the effect on pain is less consistent.⁶

Depot Injections in Mental Health Treatment

Schizophrenia treatment is one of the areas where depot injections have made the biggest difference. Missing doses of antipsychotic medication is common with daily pills and can lead to relapse and hospitalization. Long-acting injectable (LAI) antipsychotics, given every two to twelve weeks depending on the formulation, essentially take the daily decision out of the equation.

The real-world data on this is striking. A large adjusted analysis found that LAI antipsychotics were associated with a roughly 48% reduction in psychiatric hospitalizations and a 44% reduction in suicide attempts compared to oral antipsychotics.⁷ A three-year mirror-image study, where the same patients served as their own controls before and after switching to LAIs, found that average hospitalization days plummeted from about ten days to less than one, and the overall hospitalization rate dropped from about 32% to 5%.⁸

There is, however, a genuine tension in the research. When you look at randomized controlled trials alone, where participants in both the pill group and the injection group are closely monitored and reminded to take their medications, the advantage of LAIs largely disappears. A meta-analysis of 21 randomized trials involving over 5,000 patients found no significant difference in relapse prevention between LAIs and oral antipsychotics.⁹ This makes sense: in the artificial setting of a clinical trial, adherence to pills is much better than in real life. The benefit of depot injections is not pharmacological superiority but the simple guarantee that the patient actually receives the medication.

Contraception

Depot medroxyprogesterone acetate, better known as Depo-Provera, is one of the most widely used depot injection products worldwide. The standard intramuscular version delivers 150 mg and is given every three months. A lower-dose subcutaneous version (104 mg) provides comparable protection, suppressing ovulation for more than 13 weeks in all subjects studied, and the protection was not affected by body weight or race.¹⁰ Injection in the upper arm has also been shown to provide sufficient drug levels for the full 13-week interval.¹¹

Research has even explored the possibility of extending dosing intervals. A proof-of-concept trial found that no ovulations occurred for seven months after a single 150 mg subcutaneous injection, suggesting that twice-yearly dosing could be feasible with a grace period for reinjections.¹² One thing users should know: the median time for return to ovulation after stopping the standard formulation is about 30 weeks, though the vast majority of women ovulate again within a year.¹⁰ If you are planning to conceive in the near future, this delayed return to fertility is worth factoring in.

HIV Prevention and Treatment

Injectable cabotegravir, given every two months, has changed the landscape of HIV prevention. In two large phase III trials, the long-acting injectable form of cabotegravir was substantially more effective at preventing HIV than daily oral pre-exposure prophylaxis (PrEP) pills. Among men who have sex with men and transgender women, the injectable cut the rate of new HIV infections by about 69% compared to daily pills. Among cisgender women in sub-Saharan Africa, the reduction was even larger, roughly 89%.¹³

For people already living with HIV, a combination of injectable cabotegravir and rilpivirine given every four or eight weeks has been shown to maintain viral suppression as effectively as daily oral antiretroviral regimens. In long-term follow-up, viral suppression was maintained in the vast majority of participants through over three years of treatment.¹⁴ The appeal goes beyond efficacy. Qualitative research with participants in clinical trials found that many valued the injectable format for its convenience, the privacy it offered (no pill bottles for someone to find), and freedom from a daily reminder of their HIV status. Some participants noted that carrying pills across international borders posed a risk of unwanted disclosure, a problem the injection schedule eliminated.¹⁵

Opioid Use Disorder

Monthly subcutaneous buprenorphine (marketed as Sublocade) represents another area where depot injections solve a real adherence challenge. Buprenorphine is a highly effective treatment for opioid addiction, but the daily sublingual version requires consistent self-administration, and some of the medication can be diverted. The depot version delivers therapeutic blood levels from the first injection and maintains them throughout the monthly dosing interval.¹⁶

Twelve-month retention rates in clinical studies were around 50%, which is considered reasonable for this population.¹⁷ One useful feature: pharmacokinetic modeling showed that drug levels decrease slowly after the last injection, and even a two-week delay in a scheduled dose would not meaningfully impact effectiveness.¹⁶ That kind of forgiveness in the dosing schedule is a practical advantage for people whose lives may not run on a rigid calendar.

How Drug Levels Compare to Daily Pills

One of the pharmacological selling points of depot injections is smoother drug levels. When you swallow a pill, blood levels spike shortly after absorption and then fall until the next dose. This peak-to-trough swing can be clinically relevant, especially with antipsychotics, where high peaks may cause side effects and low troughs may leave you underprotected. With depot formulations, the slow release from the tissue reservoir can flatten this curve considerably.

For some injectable antipsychotics, the peak-to-trough fluctuation is comparable to or even less than what you see with daily extended-release oral pills.¹⁸ Olanzapine long-acting injection illustrates the mechanism well: its half-life in the body is around 30 days, driven not by how quickly the body eliminates olanzapine (which happens in about 30 hours with the oral version) but by how slowly the drug absorbs from the intramuscular depot. Each new injection builds on the residual drug from the previous one, and steady-state concentrations are typically reached after about three months.¹⁹ The clinical upside is that once you are at steady state, your day-to-day drug exposure barely changes.

Risks and Downsides

The flip side of a long-acting formulation is that if something goes wrong, you cannot just stop taking the pill. Once the depot is injected, the drug is in your body for weeks or months. If you develop an adverse reaction, there is no way to remove the medication. This is why many clinicians prefer to establish tolerability with a short course of the oral version before committing a patient to a depot formulation.

Injection-site reactions are the most common complaint. These range from mild pain and redness to more persistent lumps. In rare cases, the polymer microspheres used in some depot products can trigger a granulomatous reaction, where the body’s immune system walls off the foreign material into a firm nodule. Case reports have described patients on a leuprorelin acetate depot (used in prostate cancer treatment) developing subcutaneous nodules five to six centimeters across after the depot formulation was changed from a one-month to a three-month version. These lumps can be alarming enough to be mistaken for tumors.²⁰ This is uncommon, but it underscores an important point: depot injections are medical procedures, not just “strong pills,” and they carry procedure-specific risks that oral medications do not.

There is also the issue of autonomy and coercion, particularly in psychiatric treatment. Because LAI antipsychotics guarantee that medication is delivered regardless of whether the patient would choose to take a pill on a given day, they exist in an ethical grey area. Voluntary use by patients who prefer not to worry about daily pills is straightforwardly positive. Court-ordered use raises harder questions that clinicians and ethicists continue to debate.

What Patients Actually Think

Patient preferences are more nuanced than many clinicians expect. In surveys of people with schizophrenia, those who preferred LAIs most often cited ease (“LAIs are easier for me” at 67%) and the freedom from daily medication decisions (“more in control / don’t have to think about taking medicine” at 64%).²¹ Among those who preferred pills, the most distinctive reason was feeling “less embarrassed” (46%), suggesting that for some people, the clinic visit required for an injection carries social stigma that swallowing a pill at home does not.

In the HIV treatment space, similar themes emerge. Participants in a long-acting cabotegravir/rilpivirine trial described willingness to tolerate injection-site soreness in exchange for not having a daily pill that could reveal their HIV status. Travel, social situations, and the psychological weight of a daily medication ritual all factored into their preference for injections.¹⁵ The takeaway is that the “best” format depends heavily on a person’s circumstances, values, and what they find most burdensome about their treatment.

The Cost Question

Depot injections tend to cost more per dose than their oral equivalents, sometimes dramatically more. In one analysis of schizophrenia treatment, monthly medication costs for LAI antipsychotics averaged roughly $10,700 compared to about $655 for oral versions. Yet the LAI group had substantially fewer hospital admissions and emergency room visits, so total healthcare costs over 12 months were essentially the same between the two groups.²² The drug itself costs more; the downstream crises cost less. Which line item an insurer or health system focuses on can determine whether the depot option is readily available to patients.

For injectable PrEP, cost-effectiveness modeling has estimated the cost per quality-adjusted life year gained at roughly $55,000 to $110,000, depending on assumptions about user behavior. In populations with higher risk and lower baseline adherence to daily pills, the injectable looks more cost-effective. In populations already using oral PrEP consistently, the added cost is harder to justify on purely economic grounds.²³

Cancer Hormone Therapy

Depot injections are a mainstay in the hormonal treatment of prostate cancer. Gonadotropin-releasing hormone (GnRH) agonist depots suppress testosterone production, which most prostate cancers depend on for growth. These come in one-month, three-month, four-month, and six-month formulations. The six-month versions, including leuprolide acetate 45 mg and triptorelin pamoate 22.5 mg, achieved castrate-level testosterone suppression in 93% to 99% of patients in their pivotal trials, matching the efficacy and safety of shorter-interval formulations while cutting clinic visits in half.²⁴ For patients already managing the burden of cancer treatment, fewer required visits can meaningfully improve quality of life.

Depot Injections in Veterinary Medicine

The depot principle works across species, and veterinary medicine has adopted long-acting injectables extensively, particularly for livestock parasite control. Treating a herd of cattle with daily oral medications is impractical, so depot formulations that provide months of protection are ideal. A long-acting injectable formulation of moxidectin, given as a single subcutaneous injection, provided 90 days or more of continuous protection against several major cattle parasites, with efficacy against some species lasting up to 150 days.²⁵

Long-acting ivermectin has also been tested against cattle parasites. In a trial targeting Onchocerca ochengi (a parasite closely related to the worm that causes river blindness in humans), a single subcutaneous injection of long-acting ivermectin cleared skin microfilariae completely within six months, while untreated control animals still had high parasite loads.²⁶ Beyond the direct veterinary benefit, researchers are interested in whether long-acting injectable ivermectin in cattle could serve as a model for developing human formulations against neglected tropical diseases, where treatment adherence in remote areas is a persistent challenge.